Hela细胞的microRNA芯片分析及β-谷甾醇的抑癌路径预测  

Analysis of miRNAs microarray data and anti-cancer pathway prediction of β-sitosterol

作　　者：费喜佳[1] 徐德昌[1] 

机构地区：[1]哈尔滨工业大学食品科学与工程学院,哈尔滨150090

出　　处：《生物信息学》2012年第1期20-26,共7页Chinese Journal of Bioinformatics

摘　　要：天然产物β-谷甾醇对子宫癌的治疗具有较显著的功效,目前已被应用到癌症的临床治疗中,它对人体的正常细胞的毒副作用要远小于顺铂这类传统药物。目前人们对β-谷甾醇的抗癌机理知之甚少。本研究主要利用TaqMan MicroRNA As-say芯片技术对β-谷甾醇和顺铂处理过的Hela细胞进行分子水平检测,分析两种药物处理前后Hela细胞中microRNA表达水平的差异,得到在β-谷甾醇和顺铂两种药物作用下同时差异表达的microRNA,并结合多种数据库的使用进行靶标预测,频数分析及功能富集分析得到与癌症相关的靶标STK4/MST1,从生物信息学角度上推测β-谷甾醇可能抑癌路径。It has remarkable efficacy to treat cervical cancer cell using β-sitosterol.At present,β-sitosterol has been used in the clinical treatment of cancer and it＇s side effects is remotely less than the traditional drug such as cisplatin.However,the anticancer mechanism of β-sitosterol is unknown in cervical cancer.In this study,we mainly use TaqMan MicroRNA Assay to detect the consequence of Hela cell treatment by β-sitosterol and cisplatin and analyze it from molecular level.we find out the differentially expressed microRNAs and forecast their targets by Targetscan.We also provide direct evidence that STK4/MST1 is a functional target.From the view point of bioinformatics,we speculate the possible pathway of beta sitosterol to inhibit tumor.

关 键 词：Β-谷甾醇 芯片 STK4/MST1 HELA 

分 类 号：R737.33[医药卫生—肿瘤]